Biomodulin T is a Cuban injectable product based on bovine thymus extract, genenerated by the National Center for Biopreparations for immune dysfunction and the treatment for recurrent infections in older adults

Havana, May 22 (RHC) Cuban president Miguel Díaz-Canel ordered the prescription of Biomodulin T in primary health care during a meeting with scientists and experts, given the successful results of several clinical trials with this medicine.

After learning about the effectiveness of the drug in the most recent studies, the president recommended taking advantage of its confirmed preventive effect on acute respiratory infections (ARI) and the installed productive capacities, in addition to extending the use of Biomodulin T to Cuban communities.

Biomodulin T solves health situations for two very important population groups due to the demographic characteristics of the country: the elderly and children.

It is an injectable product, based on bovine thymus extract, generated by the National Center for Biopreparations (BioCen) for immune dysfunction and the treatment of recurrent infections in older adults.

Anti-inflammatory effects are also attributed to this drug, and its value is recognized in the treatment of autoimmune diseases such as Multiple Sclerosis, Rheumatoid Arthritis and Hepatitis B.

At the meeting, the director of Research and Development of BioCen, Alexis Labrada, explained that after a clinical trial in almost nine thousand patients admitted to nursing homes, reduced the incidence of acute respiratory infections by 70 percent, and therefore halved the risk of death from this cause in older adults.

According to Labrada, Biomodulin T was also studied with very good results in oncology, from combined treatment with cancer chemotherapy and immunotherapy. The immune system of the patients is rejuvenated, and they then have more capacity to counteract the disease.

Although the drug is supported by excellent efficacy and safety results, publications, and more than 20 years of use in clinical practice by immunologists, it was during the Covid-19 pandemic that it reached great notoriety by significantly reducing morbidity and mortality in older adults.

With health registration in Cuba since 1994, this drug obtained two awards from the Academy of Sciences in 2022 for its results as part of the treatment of patients with lung cancer and its immunomodulatory effects in elderly people residing in nursing homes. (Source: PL)